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0009-9260/ 2014 The Royal College of Radiologists.AIM: To investigate the feasibility and procedural value of catheter-directed contrast-
enhanced ultrasound (CCEUS) compared with catheter-directed computed tomography arte-
riography (CCTA) in patients undergoing transarterial chemoembolization (TACE) guided by
digital subtraction angiography (DSA).
MATERIALS AND METHODS: From December 2010 to December 2011, a pilot study was
conducted including nine patients (mean age 66.6 years; SD 8.3 years; seven men) undergoing
TACE with drug-eluting beads for unresectable hepatocellular carcinoma (HCC). Both CCEUS
and CCTA were performed in addition to DSA. Alterations of treatment plan based on CCEUS
were recorded and compared with CCTA.
RESULTS: CCEUS provided additional information to DSA altering the treatment plan in four
out of nine patients (44.4%). In these four patients, CCEUS helped to identify additional tumour
feeders (n ¼ 2) or led to a change in catheter position (n ¼ 2). The information provided by
CCEUS was similar to that provided by CCTA.
CONCLUSION: CCEUS is a potentially valuable imaging tool in adjunction to DSA when
performing TACE and may provide similar information to CCTA.
 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.Introduction
Transarterial chemoembolization (TACE) improves sur-
vival in patients with intermediate-stage hepatocellular
carcinoma (HCC).1e3 Traditionally, TACE is guided by digitals, Albinusdreef 2, 2300 RC
x: þ31 715248256.
.C. Burgmans).
Published by Elsevier Ltd. All righsubtraction angiography (DSA). Yet the information ob-
tained with DSA is limited as DSA only allows two-
dimensional imaging. Different studies have shown the
value of catheter-directed computed tomography arteriog-
raphy (CCTA) and cone-beam computed tomography (CBCT)
when performing transarterial liver therapies.4e8 These
techniques allow accurate multiplanar visualization of
tumour enhancement and improve identification of
tumour-feeding arteries. The image quality of CCTA ists reserved.
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resolution and CCTA allows imaging with a larger field of
view.9
Contrast-enhanced ultrasound with catheter-directed
intra-arterial injection (CCEUS) may potentially be a good
alternative to CCTA or CBCT. CCEUS enables real-time
visualization of tumour enhancement in multiple di-
rections. Moreover, it is widely available and does not
expose the patient to radiation. The aim of this prospective
pilot study was to evaluate the procedural impact of CCEUS
when used in addition to DSA to guide TACE with drug-
eluting beads in patients with intermediate stage HCC and
to compare CCEUS with CCTA.
Materials and methods
Patients
The study was improved by the local ethics committee.
Informed consent was obtained for all study patients. From
December 2010 to December 2011, nine consecutive pa-
tients with HCC were included in the study (mean age 66.6
years; SD 8.3 years; seven men). Inclusion criteria for the
study were: unresectable HCC, ChildePugh A or B and
Eastern Cooperative Oncology Group (ECOG) performance
status <2. The diagnosis of HCC was confirmed according to
American Association for the Study of Liver Diseases
(AASLD) practice guidelines criteria.10 Exclusion criteria
were age <18 years, diffuse HCC or more than five lesions,
previous treatment with TACE or radioembolization,
advanced-stage disease according to Barcelona Clinic Liver
Cancer (BCLC) criteria,11 total bilirubin >3 mg/dl, uncor-
rectable coagulopathy, end-stage renal failure, any contra-
indication to doxorubicin, known hypersensitivity to
sulphur hexafluoride (SF6) micro-bubbles, known right-to-
left intra-cardiac shunts, severe pulmonary hypertension,
and pregnancy.
The study was performed in accordance with the
Declaration of Helsinki, the International Conference on
Harmonization Guideline on Good Clinical Practice and
relevant local laws and regulations.
Design and procedures
All patients enrolled in the study underwent grey-scale
ultrasonography in the angiography room prior to TACE.
In addition to this, contrast-enhanced ultrasound was per-
formedwith injection of 2.4 ml SF6microbubbles (SonoVue,
Bracco International, Amsterdam, The Netherlands)
through a cannula in the median cubital vein (IVCEUS).
Additional boluses of 2.4 ml of microbubbles were given, if
the distance between different tumours was such that the
enhancement of each tumour could not be analysed opti-
mally during a single injection. Sufficient time was allowed
between injections for the first bolus of microbubbles to be
cleared from the body.
The right groin and upper abdomen were cleansed with
iodine and the patient was draped under sterile cloths with
exposure of the right groin and upper abdomen. Vascularaccess was created through the right common femoral ar-
tery using a 6 F vascular sheath. Using a 5 F C2 catheter
(Terumo, Tokyo, Japan) selective DSA from the coeliac axis
(CA), common hepatic artery (CHA), and proper hepatic
artery (PHA) was performed with pump injection of a
contrast agent (iohexol, 300mg iodine/ml; Omnipaque 300,
GE Healthcare, Shanghai, China). Angiography from the
superior mesenteric artery (SMA) was performed in indi-
vidual cases when hepatic tumour supply from an aberrant
right hepatic artery or other SMA branches was expected
based on pre-procedural CT or magnetic resonance imaging
(MRI). Immediately after DSA from the PHA and using the
same catheter position, CCEUS was performed followed by
CCTA. A 2.2 or 2.7 F Progreat catheter (Terumo, Tokyo,
Japan) was then used to catheterize the lobar artery of the
tumour-bearing lobe(s) and selective DSA was performed.
Again, this was followed by CCEUS and then CCTA with the
micro-catheter in the same position. Finally, the (sub)
segmental arteries were catheterized using the micro-
catheter and sequential DSA, CCEUS, and CCTA were per-
formed. In patients with bi-lobar disease, imaging at a lobar
and (sub)segmental level was first performed on one side
followed by TACE of the tumours in that lobe. After that,
images were obtained at a lobar and (sub)segmental level
on the other side and the tumours in the other lobe were
treated.
DSA images were obtained with breath-hold, 3 frames/s
and 50 mAs/120 kV for anteroposterior projections. Using a
Mark V ProVis injector (Medrad, Warrendale, PA, USA),
contrast mediumwas injected at 6 ml/s for 25ml for the CA,
5 ml/s for 15 ml for the PHA, 3 ml/s for 12 ml for lobar in-
jections, and 1e2 ml/s for 6e10 ml for (sub)segmental in-
jections. CCEUS was performed using contrast harmonic
imaging on a high-performance processor (Aplio, Toshiba
Medical Systems, Tokyo, Japan) with a multifrequency
curved-array probe (2e5 MHz). SF6 micro-bubbles were
slowly hand-injected. Injections of 1 ml were used for the
PHA, 0.5 ml for the lobar artery and 0.3e0.5 ml for (sub)
segmental arteries. During the injection, the entire tumour
volume was scanned to assess the presence of unenhancing
areas. CCTA was performed using a hybrid 16-section
Aquilion CT/Infinix VC-1 angiography system (Toshiba
Medical Systems, Tokyo, Japan). Pump injections were used
with an injection rate similar to that used for DSA. The
injected contrast medium volume for CCTA was calculated
using the equation
volume ¼ ðscan delayþ scan timeÞ  flow rate
with the scan delay being the time between the start of
injection and enhancement of the region of interest at DSA.
CCTA images were acquired using the following parame-
ters: 16  1 collimation, pitch factor ¼ 15, helical
pitch ¼ 0.938, 120 kV tube voltage and 160 effective mAs
tube current. The radiation dose used to perform CCTA was
recorded as doseelength product (DLP) per patient.
All patients underwent super-selective TACE with the
micro-catheter placed as selectively as possible. TACE was
performed with DC-Beads (Biocompatibles, Surrey, UK).
Table 1
Baseline patient and tumour characteristics.




Sex M ¼ 7
Performance status (n ¼ 9)
0 8 (88.9)
1 1 (11.1)
Cause of cirrhosis (n ¼ 9)
Hepatitis B 6 (66.7)
Alcohol 2 (22.2)
NASH 1 (11.1)
ChildePugh score (n ¼ 9)
A 8 (88.9)
B 1 (11.1)
Tumour burden (n ¼ 9)
Unilobar 6 (66.7)
Bilobar 3 (33.3)
No. nodules (n ¼ 9)
1e3 8 (88.9)
>3 1 (11.1)





Data are n(%) unless otherwise stated.
M.C. Burgmans et al. / Clinical Radiology 69 (2014) 1056e10611058First, one vial of 100e300 mm beads was injected, followed
by one vial of 300e500 mm beads. The beads were loaded
with a total of 150 mg doxorubicin (75 mg per vial) and
mixed with contrast medium prior to injection.
All patients underwent repeated IVCEUS immediately
after TACE. Both IVCEUS and CCEUS were performed by the
interventional radiologist performing the procedure. All
IVCEUS and CCEUS images were archived digitally for re-
view as cine loops in Windows Media Videos (Microsoft,
Redmont, WA, USA).
Imaging analysis
At the time of the procedure, DSA images were analysed
by the interventional radiologist performing the procedure
and a treatment plan was formulated. CCEUS images were
then analysed to see whether CCEUS provided additional
information to DSA. CCEUS images were compared to pre-
procedural IVCEUS images. If incomplete tumour enhance-
ment was seen at CCEUS from the hepatic arteries, this
prompted a search for extra-hepatic feeding arteries. If
tumour enhancement was incomplete upon CCEUS from a
lobar or (sub)segmental artery, but not upon CCEUS from a
more proximal hepatic artery injection, the catheter was
repositioned more proximally prior to injection of DC-
Beads. The information obtained with CCEUS was classi-
fied into three categories1: no change in treatment plan2;
identification of additional tumour feeding arteries3; alter-
ation in location of injection of the drug-eluting beads. After
this, CCTA images were analysed to see whether CCTA
provided information not evident on DSA and CCEUS.
IVCEUS images obtained before and after TACE were
retrospectively compared to see whether complete devas-
cularization of the tumours was achieved.Results
Patient and tumour characteristics are summarized in
Table 1. Nineteen HCCs were identified on pre-procedural
cross-sectional imaging (CT and/or MRI) with an average
of 2.1 (range 1e5) tumours per patient. The mean maximal
tumour size was 45.3 mm (range 10e145 mm).
In four patients (44.4%), the information provided by
CCEUS was not evident at DSA and led to a change of
treatment plan. In two of these four patients (22.2% of total)
CCEUS led to identification of additional tumour-feeding
arteries. Both patients had a right liver lobe tumour with
a dominant vascular supply from the right hepatic artery. At
DSA from the right hepatic artery, incomplete tumour
enhancement was not evident. Yet, at CCEUS, there was
incomplete enhancement of the tumour and this eventually
helped in identifying additional tumour supply from the
middle hepatic artery (Fig 1). In the two other patients
(22.2%), CCEUS provided information that led to a change in
the decision onwhere to inject the DC-Beads. In these cases
CCEUS enabled more selective chemo-embolization while
ensuring that the entire tumour was accurately targeted
(Fig 2).In four patients where CCEUS provided information that
led to a change in treatment, CCTA provided the same in-
formation (Figs 1 and 2). CCTA did not provide additional
information that led to a change in treatment plan.
The use of CCTA did result in additional information on
extra-hepatic enhancement that was not provided by DSA
and CCEUS. In four patients (44.4%), CCTA revealed
enhancement of the gallbladder (GB; n ¼ 1), the hepatic
falciform artery (HFA; n¼ 2), or both the GB and HFA (n¼ 1)
when contrast medium was injected from the intended
location of release of the drug-eluting beads. This infor-
mation did not alter the treatment plan. None of these four
patients developed complications related to injection of
drug-eluting beads into the cystic artery or HFA.
IVCEUS immediately after TACE showed complete
devascularization of liver tumours in five patients (55.6%).
The four patients with residual enhancement at IVCEUS all
had large liver tumours (>10 cm). In these patients, vascular
stasis was not achieved after delivery of the full dose of
drug-eluting beads and the decision was made to treat the
remaining viable tumour during a second TACE procedure.
The area of residual enhancement on IVCEUS corresponded
to the vascular territory of the supplying artery that was not
completely embolized, indicating that residual enhance-
ment was not a result of failure to detect additional tumour-
feeding arteries.
The mean DLP per patient was 921.5 mGy cm
(SD ¼ 371.7 mGy cm).
Discussion
The objective of TACE is to accurately target the entire
tumour while preserving the non-tumorous liver
Figure 1 A 58-year-old man with right liver lobe HCC with a maximal diameter of 12 cm. (a) DSA image from the CA shows tumour
enhancement (asterisk) through the right hepatic artery (RHA; arrow). There is a left hepatic artery (LHA) that originates from the left gastric
artery (arrowhead). No middle hepatic artery (MHA) is seen. (b) CCEUS (left) and B-mode (right) images during injection of SF6 microbubbles
into the RHA. Marked arterial enhancement of the tumour (arrowheads) is seen compared to the non-tumorous liver parenchyma (cross-mark).
(c) CCTA image from the RHA also shows absent enhancement in part of the tumour (asterisk). (d) DSA image from the superior mesenteric
artery shows retrograde flow through the gastroduodenal artery (GDA; arrow) and opacification of the MHA (black arrowhead) and a second
LHA (white arrowhead). The MHA and LHA have an origin from the CA that was not opacified at DSA from the CA due to the reversed flow
through the GDA. (e) CCEUS (left) image from the MHA shows tumour supply (asterisk) through the MHAwith absent enhancement in the rest of
the tumour (cross-mark). (f) CCTA image from the MHA also shows enhancement of part of the tumour through the MHA.
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generally recommended to deliver the beads as selectively
as possible.12 Super-selective injection, i.e., into the
segmental or sub-segmental arteries, is associated with
better treatment outcomes compared to lobar or whole-
liver chemoembolization.13
DSA is used to guide the delivery of the drug-eluting
beads. Yet, DSA only enables two-dimensional imaging. As
a result, incomplete tumour enhancement may not be
detected during hepatic DSA. This is especially true if the
non-enhancing areas of the tumour are located anterior or
posterior as hepatic DSA images are usually obtained in the
posterioreanterior or moderately oblique projections.
There are two important causes for incomplete tumour
enhancement during hepatic DSA. The most important
cause is the presence of extra-hepatic feeding arteries.
Unfortunately, up to 37% of patients with HCC may have a
collateral tumour supply through extra-hepatic arteries.5
Second, incomplete tumour enhancement may be due to a
highly selective catheter position. Treatment at a (sub)
segmental level carries the risk that the catheter is placed
distally to additional hepatic feeders. Failure to detect ab-
sent enhancement of tumour parts during hepatic DSA may
thus result in incomplete tumour treatment.
Different studies have shown that catheter-directed
cross-sectional imaging, such as CCTA and CBCT, allow ac-
curate multiplanar visualization of tumour enhancementandmay improve tumour targeting.4e8 In the present study,
CCEUS was compared to CCTA as an adjunct to DSA to guide
TACE. CCEUS proved to be safe and feasible. In 44.4% of
patients, CCEUS provided information that was not evident
at DSA and altered the treatment approach. The additional
information provided by CCEUS was similar to that pro-
vided by CCTA. Although the number of patients in te pre-
sent study is limited, the findings suggest that CCEUS may
improve trans-arterial liver tumour targeting, as does CCTA.
In a viable tumour, incomplete enhancement upon contrast
medium injection from the hepatic arteries may indicate
extra-hepatic tumour supply. Complete tumour enhance-
ment upon contrast medium injection from a super-
selective hepatic artery position allows the operator to
feel confident that the entire tumour is targeted, whereas
incomplete enhancement may prompt the search for
additional feeding hepatic arteries. CCEUS offers an
important advantage over CCTA. It can be repeated multiple
times without increasing iodinated contrast medium vol-
ume or radiation, whereas CT imaging during TACE results
in a significant increase of the radiation dose to both the
patient and operating staff.14,15
Few centres have access to a hybrid CT/angiography
system that allows CCTA images to be obtained without
moving a patient between rooms. CBCT is available to many
more interventional radiologists and is much more
frequently used as an adjunct to DSA during TACE. CCEUS
Figure 2 A 79-year-old man with a 4.5 cm HCC at the border of segment 6 and the caudate lobe. (aeb) DSA image from the common hepatic
artery (black arrow) in the arterial (a) and parenchymal (b) phase with opacification of the tumour (white arrow). (c) CCEUS image from the
subsegmental artery showed complete tumour enhancement (white arrow) with enhancement of a small portion of non-tumorous liver pa-
renchyma (arrowhead) and no enhancement of most of the right liver lobe (asterisk). (d) CCTA confirmed enhancement of the entire tumour
upon injection of contrast medium into the subsegmental artery. CCEUS and CCTA thus ensured complete tumour targeting by injection of drug-
eluting beads into the subsegmental artery. IVCEUS directly after treatment and CT at 6 weeks showed complete devascularization of the tumour
(not shown).
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CCEUS may offer several additional advantages over CBCT.
CBCT has a relatively long acquisition time (8e20 s) making
this technique more susceptible to breathing artefacts,
whereas breathing is not an issue in CCEUS. Another
drawback of CBCT is the limited field of view (FOV). CCEUS is
less hindered by limitations in the FOV as it can be repeated
multiple times to cover larger areas without radiation or
risk of contrast medium-induced nephropathy.
The standard volume of SF6 microbubbles of hepatic
IVCEUS at the time of the study was 2.4 ml. Modern high-
end ultrasound machines enable good-quality IVCEUS im-
aging with lower dosages and may, therefore, also allow the
use of lower volumes of microbubbles for CCEUS then those
used in the present study.
The main limitation of the present study is the limited
number of patients. Second, the usefulness of CCEUS was
not compared with CBCT, which is more widely used than
CCTA. Yet, CCTA was used as the gold standard in the pre-
sent study as this technique has better image quality and a
larger FOV compared to CBCT. Furthermore, CCEUS was
inferior to CCTA in providing information on extra-hepaticenhancement. Yet, the information provided by CCTA did
not alter the treatment strategy and no extra-hepatic organ
injury was seen.
In conclusion, CCEUS is a potentially useful imaging tool
in adjunction to DSAwhen performing TACE. It may provide
similar multiplanar information on tumour enhancement to
CCTA without increasing iodinated contrast medium vol-
ume or radiation, yet further studies are warranted to
determine the role of CCEUS.Acknowledgement
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